跳至主要内容
临床试验/NCT00985036
NCT00985036撤回不适用

Is VEGF a Useful Serum Biomarker for Patients Diagnosed With Meningioma or Glioma?

Marquette General Health System1 个研究点 分布在 1 个国家开始时间: 2009年9月最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
试验地点
1
主要终点
Determine if VEGF levels correlate with tumor progression or recurrence

研究概览

简要总结

Objectives: This study is looking at the level of vascular endothelial growth factor (VEGF) circulating in the blood stream of patients diagnosed with either a meningioma or a glioma. The questions that will be addressed include:

  1. Can VEGF level alert us to tumor progression or recurrence before MRI changes occur?
  2. Is the VEGF level an indicator of the response to treatment?
  3. Does the VEGF level correlate with tumor histology and behavior?
  4. Is there a relationship between VEGF level and outcome?

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • any patient presenting with glioma or meningioma

排除标准

  • a different type of brain tumor

结局指标

主要结局

Determine if VEGF levels correlate with tumor progression or recurrence

时间窗: every one to three months

次要结局

  • Determine if the VEGF level is an indicator of the response to treatment.(Every one to three months)
  • Determine if the VEGF level correlates with tumor histology and behavior.(Every one to three months)
  • Determine if there is a relationship between VEGF level and outcome.(Every one to three months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Richard A. Rovin, MD FACS

Neurosurgeon

Marquette General Health System

研究点 (1)

Loading locations...

相似试验